{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:31:24Z","timestamp":1792211484612,"version":"4.4.0"},"reference-count":44,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0323-0","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T13:12:14Z","timestamp":1518441134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients"],"prefix":"10.1136","volume":"6","author":[{"given":"Michael T.","family":"Tetzlaff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly C.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg A.","family":"Staerkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadharsini","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Torres-Cabala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Chasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Wargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor G.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodabe N.","family":"Amaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,2,12]]},"reference":[{"issue":"8","key":"323_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"4","key":"323_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"1","key":"323_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1517\/17425255.2016.1120287","volume":"12","author":"C Ciccarese","year":"2016","unstructured":"Ciccarese C, Alfieri S, Santoni M, Santini D, Brunelli M, Bergamini C, et al. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(1):57\u201375.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"323_CR4","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/cup.12717","volume":"43","author":"G Jour","year":"2016","unstructured":"Jour G, Glitza IC, Ellis RM, Torres-Cabala CA, Tetzlaff MT, Li JY, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016;43(8):688\u201396.","journal-title":"J Cutan Pathol"},{"issue":"2","key":"323_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cup.12858","volume":"44","author":"JL Curry","year":"2017","unstructured":"Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44(2):158\u201376.","journal-title":"J Cutan Pathol"},{"issue":"2","key":"323_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","volume":"39","author":"MT Tetzlaff","year":"2017","unstructured":"Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, et al. Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the Clinicopathologic features. Amer J Dermatopathol. 2017;39(2):121\u201329.","journal-title":"Amer J Dermatopathol"},{"issue":"8","key":"323_CR7","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.954506","volume":"3","author":"R Andersen","year":"2014","unstructured":"Andersen R, Norgaard P, Al-Jailawi MK, Svane IM. Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. Oncoimmunology. 2014;3(8):e954506.","journal-title":"Oncoimmunology"},{"issue":"3","key":"323_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jdcr.2016.05.002","volume":"2","author":"KC Suozzi","year":"2016","unstructured":"Suozzi KC, Stahl M, Ko CJ, Chiang A, Gettinger SN, Siegel MD, et al. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep. 2016;2(3):264\u201368.","journal-title":"JAAD Case Rep"},{"issue":"3","key":"323_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jdcr.2017.02.015","volume":"3","author":"MR Birnbaum","year":"2017","unstructured":"Birnbaum MR, Ma MW, Fleisig S, Packer S, Amin BD, Jacobson M, et al. Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma. JAAD Case Rep. 2017;3(3):208\u201311.","journal-title":"JAAD Case Rep"},{"issue":"7","key":"323_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamadermatol.2017.0581","volume":"153","author":"S Burillo-Martinez","year":"2017","unstructured":"Burillo-Martinez S, Morales-Raya C, Prieto-Barrios M, Rodriguez-Peralto JL, Ortiz-Romero PL. Pembrolizumab-induced extensive Panniculitis and nevus regression: two novel Cutaneous manifestations of the post-immunotherapy Granulomatous reactions Spectrum. JAMA Dermatol. 2017;153(7):721\u201322.","journal-title":"JAMA Dermatol"},{"key":"323_CR11","doi-asserted-by":"crossref","unstructured":"Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Rao BK, Landone G, Nagarajan P, Choksi AN, Chen L, Uemura M, Aung PP et al: Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy. Report of two patients. J Cutan Pathol. 2017;44(12):1080-86.","DOI":"10.1111\/cup.13044"},{"issue":"12","key":"323_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.75","volume":"5","author":"WM Timmermans","year":"2016","unstructured":"Timmermans WM, van Laar JA, van Hagen PM, van Zelm MC. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology. 2016;5(12):e118.","journal-title":"Clin Transl Immunology"},{"issue":"9923","key":"323_CR13","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","volume":"383","author":"D Valeyre","year":"2014","unstructured":"Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Muller-Quernheim J. Sarcoidosis. Lancet. 2014;383(9923):1155\u201367.","journal-title":"Lancet"},{"issue":"2","key":"323_CR14","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/cancers7020821","volume":"7","author":"BD Beutler","year":"2015","unstructured":"Beutler BD, Cohen PR. Sarcoidosis in melanoma patients: case report and literature review. Cancer. 2015;7(2):1005\u201321.","journal-title":"Cancer"},{"issue":"8","key":"323_CR15","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1177\/1078155216667635","volume":"23","author":"B Firwana","year":"2017","unstructured":"Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract. 2017;23(8):620\u201324.","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"323_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000161122","volume":"218","author":"A Eckert","year":"2009","unstructured":"Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology. 2009;218(1):69\u201370.","journal-title":"Dermatology"},{"issue":"1","key":"323_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000213245","volume":"219","author":"P Seve","year":"2009","unstructured":"Seve P, Schott AM, Pavic M, Broussolle C, Gilis L, Thomas L. Sarcoidosis and melanoma: a referral center study of 1,199 cases. Dermatology. 2009;219(1):25\u201331.","journal-title":"Dermatology"},{"issue":"2","key":"323_CR18","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1200\/JCO.2011.37.9693","volume":"30","author":"WV Vogel","year":"2012","unstructured":"Vogel WV, Guislain A, Kvistborg P, Schumacher TN, Haanen JB, Blank CU. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol. 2012;30(2):e7\u2013e10.","journal-title":"J Clin Oncol"},{"issue":"4","key":"323_CR19","first-page":"1355","volume":"32","author":"S Wilgenhof","year":"2012","unstructured":"Wilgenhof S, Morlion V, Seghers AC, Du Four S, Vanderlinden E, Hanon S, et al. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res. 2012;32(4):1355\u201359.","journal-title":"Anticancer Res"},{"issue":"17","key":"323_CR20","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1200\/JCO.2011.39.3298","volume":"30","author":"G Berthod","year":"2012","unstructured":"Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Mazza Stalder J, et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol. 2012;30(17):e156\u201359.","journal-title":"J Clin Oncol"},{"issue":"1","key":"323_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1183\/09031936.00107912","volume":"41","author":"C Tissot","year":"2013","unstructured":"Tissot C, Carsin A, Freymond N, Pacheco Y, Devouassoux G. Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy. Eur Respir J. 2013;41(1):246\u201347.","journal-title":"Eur Respir J"},{"issue":"5","key":"323_CR22","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/j.jaad.2013.07.028","volume":"69","author":"RB Reule","year":"2013","unstructured":"Reule RB, North JP. Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. J Am Acad Dermatol. 2013;69(5):e272\u201373.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"323_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000362614","volume":"37","author":"KP Murphy","year":"2014","unstructured":"Murphy KP, Kennedy MP, Barry JE, O'Regan KN, Power DG. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat. 2014;37(6):351\u201353.","journal-title":"Oncol Res Treat"},{"issue":"4","key":"323_CR24","doi-asserted-by":"publisher","first-page":"e1068","DOI":"10.1097\/MJT.0000000000000266","volume":"23","author":"A Toumeh","year":"2016","unstructured":"Toumeh A, Sakhi R, Shah S, Arudra SK, De Las Casas LE, Skeel RT. Ipilimumab-induced Granulomatous disease occurring simultaneously with disease progression in a patient with metastatic melanoma. Am J Ther. 2016;23(4):e1068\u201371.","journal-title":"Am J Ther"},{"issue":"5","key":"323_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","volume":"13","author":"AJ van den Eertwegh","year":"2012","unstructured":"van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):509\u201317.","journal-title":"Lancet Oncol"},{"issue":"4","key":"323_CR26","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/bjd.14808","volume":"176","author":"H Montaudie","year":"2017","unstructured":"Montaudie H, Pradelli J, Passeron T, Lacour JP, Leroy S. Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol. 2017;176(4):1060\u201363.","journal-title":"Br J Dermatol"},{"issue":"5","key":"323_CR27","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","volume":"149","author":"FX Danlos","year":"2016","unstructured":"Danlos FX, Pages C, Baroudjian B, Vercellino L, Battistella M, Mimoun M, et al. Nivolumab-induced Sarcoid-like Granulomatous reaction in a patient with advanced melanoma. Chest. 2016;149(5):e133\u201336.","journal-title":"Chest"},{"issue":"4","key":"323_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","volume":"2","author":"J Cotliar","year":"2016","unstructured":"Cotliar J, Querfeld C, Boswell WJ, Raja N, Raz D, Chen R. Pembrolizumab-associated sarcoidosis. JAAD Case Rep. 2016;2(4):290\u201393.","journal-title":"JAAD Case Rep"},{"issue":"26","key":"323_CR29","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Swu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advacned cancer. N Engl J Med. 2012;366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"2","key":"323_CR30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/039463201302600204","volume":"26","author":"C Tana","year":"2013","unstructured":"Tana C, Giamberardino MA, Di Gioacchino M, Mezzetti A, Schiavone C. Immunopathogenesis of sarcoidosis and risk of malignancy: a lost truth? Int J Immunopathol Pharmacol. 2013;26(2):305\u201313.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"3","key":"323_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.clindermatol.2007.03.010","volume":"25","author":"PR Cohen","year":"2007","unstructured":"Cohen PR, Kurzrock R. Sarcoidosis and malignancy. Clin Dermatol. 2007;25(3):326\u201333.","journal-title":"Clin Dermatol"},{"issue":"3","key":"323_CR32","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/1097-0142(197503)35:3<756::AID-CNCR2820350331>3.0.CO;2-Z","volume":"35","author":"R Lieberman","year":"1975","unstructured":"Lieberman R, Wybran J, Epstein W. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma. Cancer. 1975;35(3):756\u201377.","journal-title":"Cancer"},{"issue":"7614","key":"323_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature18945","volume":"536","author":"EM Verdegaal","year":"2016","unstructured":"Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature. 2016;536(7614):91\u201395.","journal-title":"Nature"},{"issue":"5","key":"323_CR34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMcibr1613793","volume":"376","author":"VN Kristensen","year":"2017","unstructured":"Kristensen VN. The Antigenicity of the tumor cell - context matters. N Engl J Med. 2017;376(5):491\u201393.","journal-title":"N Engl J Med"},{"key":"323_CR35","doi-asserted-by":"crossref","unstructured":"Mauzo SH, Tetzlaff MT, Nelson K, Amaria R, Patel S, Aung PP, Nagarajan P et al. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. Int J Dermatol. 2017 (Epub ahead of print).","DOI":"10.1111\/ijd.13833"},{"issue":"3","key":"323_CR36","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1378\/chest.127.3.1064","volume":"127","author":"JD Doty","year":"2005","unstructured":"Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127(3):1064\u201371.","journal-title":"Chest"},{"key":"323_CR37","doi-asserted-by":"publisher","first-page":"8573","DOI":"10.4076\/1752-1947-3-8573","volume":"3","author":"SR Patel","year":"2009","unstructured":"Patel SR. Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report. J Med Case Reports. 2009;3:8573.","journal-title":"J Med Case Reports"},{"issue":"3","key":"323_CR38","first-page":"378","volume":"11","author":"A Decock","year":"2017","unstructured":"Decock A, Van Assche G, Vermeire S, Wuyts W, Ferrante M. Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy? J Crohns Colitis. 2017;11(3):378\u201383.","journal-title":"J Crohns Colitis"},{"issue":"6 Suppl 1","key":"323_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1590\/abd1806-4841.20132487","volume":"88","author":"G Santos","year":"2013","unstructured":"Santos G, Sousa LE, Joao AM. Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab--a paradoxical effect? A case report. An Bras Dermatol. 2013;88(6 Suppl 1):26\u201328.","journal-title":"An Bras Dermatol"},{"issue":"6","key":"323_CR40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/RHU.0b013e3181efa190","volume":"16","author":"RR Clementine","year":"2010","unstructured":"Clementine RR, Lyman J, Zakem J, Mallepalli J, Lindsey S, Quinet R. Tumor necrosis factor-alpha antagonist-induced sarcoidosis. J Clin Rheumatol. 2010;16(6):274\u201379.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"323_CR41","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1111\/j.1440-0960.2010.00660.x","volume":"52","author":"S Marcella","year":"2011","unstructured":"Marcella S, Welsh B, Foley P. Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis. Australas J Dermatol. 2011;52(3):e8\u201311.","journal-title":"Australas J Dermatol"},{"issue":"4","key":"323_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.semarthrit.2008.11.003","volume":"39","author":"A Massara","year":"2010","unstructured":"Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new \u201cclass effect\u201d paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum. 2010;39(4):313\u201319.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"323_CR43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1165\/rcmb.2016-0037OC","volume":"56","author":"LJ Celada","year":"2017","unstructured":"Celada LJ, Rotsinger JE, Young A, Shaginurova G, Shelton D, Hawkins C, et al. Programmed Death-1 inhibition of Phosphatidylinositol 3-Kinase\/AKT\/mechanistic target of Rapamycin signaling impairs Sarcoidosis CD4(+) T cell proliferation. Am J Respir Cell Mol Biol. 2017;56(1):74\u201382.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"323_CR44","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1164\/rccm.201006-0865CI","volume":"183","author":"RP Baughman","year":"2011","unstructured":"Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183(5):573\u201381.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0323-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:43:14Z","timestamp":1601055794000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0323-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0323-0","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,12]]},"assertion":[{"value":"28 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board at The University of Texas MD Anderson Cancer Center.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"14"}}